Upfront Immunotherapy for Metastatic Kidney Cancer
0 Tampilan
• 06/26/23
0
0
Menanamkan
administrator
Pelanggan
Panelists Robert A. Figlin, MD, and Eric Jonasch, MD, provide insight on the implications of frontline trials for immunotherapy and cabozantinib use, and the rationale for combination trials for metastatic kidney cancer.
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru